BENGALURU, India, June 24, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a global, fully integrated biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new, world-class, multi-product monoclonal antibodies (mAbs) drug substance facility at Bengaluru. This approval will provide significant additional capacity to address patients' needs across markets in Europe. The facility has previously been approved to manufacture biosimilar Trastuzumab in September 2022.

The Company also announced that EMA has renewed its Good Manufacturing Practice (GMP) Certificates of Compliance for its biosimilars manufacturing facility at Bengaluru and its insulin facility in Malaysia following routine GMP inspections. These certificates were issued by the Health Products Regulatory Authority (HPRA), Ireland, on behalf of EMA.

"These GMP certifications across our manufacturing sites in India and Malaysia reflect Biocon Biologics' continued compliance with the highest standards of quality and our unwavering commitment to addressing patient needs globally." - Company Spokesperson

For more information: www.bioconbiologics.com

Logo - https://mma.prnewswire.com/media/2143906/Biocon_Biologics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites-302180507.html

Tags

More Like This

WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates

WuXi Biologics Ireland Facility Receives EMA Approval for Commercial Manufacturing of Innovative Biologic

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

MS Pharma Establishes MENA's First Biologics Manufacturing Hub in Saudi Arabia, Advancing Regional Leadership and Global Partnerships

Thousand Oaks Biologics Shanghai ADC Site receives EU QP Declaration

Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing

WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations